Pharmaceutical composition for treating systemic lupus erythematosus comprising PIBF1 as active ingredient

The PIBF1 composition addresses the immune dysregulation in systemic lupus erythematosus and lupus nephritis by reducing autoantibodies and kidney inflammation, offering a promising treatment for these conditions by administering PIBF1 through various routes.

WO2024232591A1PCT designated stage expired Publication Date: 2024-11-14THE ASAN FOUND +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/005896
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-10
Filing Date
2024-04-30
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current treatments for systemic lupus erythematosus and lupus nephritis are inadequate in effectively managing autoimmune responses and reducing disease progression, as they fail to address the underlying immune dysregulation and autoantibody production.

Method used

A pharmaceutical composition containing Progesterone-Induced Blocking Factor 1 (PIBF1) is developed, which is administered via intraperitoneal, intravenous, or oral routes, reducing anti-dsDNA autoantibodies, urine albumin creatinine ratio, and increasing marginal zone B cells and regulatory B cells, thereby alleviating lupus disease progression.

Benefits of technology

The PIBF1 composition significantly reduces serum anti-dsDNA autoantibodies and urine albumin creatinine ratio, demonstrating therapeutic effects in lupus nephritis and preventing complications, with improved immune regulation and reduced kidney disease activity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024005896_14112024_PF_FP_ABST
    Figure KR2024005896_14112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating systemic lupus erythematosus, comprising PIBF1 as an active ingredient, and the therapeutic role of PIBF1 in a lupus mouse model was confirmed. Particularly, it was confirmed that PIBF1 exhibited excellent effects of alleviating and treating lupus disease progression by significantly reducing both anti-dsDNA autoantibodies in serum and a urine albumin / creatinine ratio (uACR), and also had an excellent effect of preventing lupus by reducing B220+ DNT cells, which are known to be increased in a mouse model susceptible to lupus, and thus the PIBF1 is expected to be effectively used as a composition for preventing or treating systemic lupus erythematosus and lupus nephritis.
Need to check novelty before this filing date? Find Prior Art

Description

Pharmaceutical composition for treating systemic lupus erythematosus containing PIBF1 as an active ingredient

[0001] The present invention relates to a pharmaceutical composition for preventing or treating systemic lupus erythematosus, comprising PIBF1 as an active ingredient.

[0002] This invention claims priority to Republic of Korea Patent Application No. 10-2023-0060305, filed May 10, 2023, the entire disclosure of which is incorporated herein by reference.

[0003]

[0004] Immunity is one of the body's self-protection systems against all foreign macromolecular substances (antigens) that invade or are injected into living tissue. A key component of the immune system is lymphocytes, white blood cells produced in the bone marrow and circulating in the bloodstream to lymphoid tissues and organs, primarily the lymph nodes, spleen, and tonsils. Lymphocytes are cells involved in immune responses. B cells, when stimulated by an appropriate antigen, rapidly proliferate and form clones that produce specific antibodies (immunoglobulins) to neutralize the antigen. The antibodies produced by B cells circulate in body fluids, carrying out humoral immunity. T cells, also produced in the thymus and migrating to lymphoid tissue, are responsible for cell-mediated immunity, directly attacking antigens.

[0005] Meanwhile, one of the most important characteristics of all normal organisms is the ability to recognize, respond to, and eliminate non-self antigens, while not reacting harmfully to the antigenic substances that constitute the self. This lack of response by the body to self-antigens is called immunological unresponsiveness or tolerance. If there is a problem in inducing or maintaining this self-tolerance, an immune response to self-antigens occurs, resulting in an attack on the body's own tissues, resulting in the development of autoimmune diseases.

[0006] Systemic lupus erythematosus (SLE) is an autoimmune disease caused by abnormal immune system responses to various factors, including genetics, environment, and hormones. Its primary characteristic is the excessive production of pathogenic autoantibodies. This immunological disorder is characterized by various symptoms, including end-organ damage throughout the body, defective clearance of apoptotic cells, and the production of pathogenic autoantibodies by plasma cells. Among the mechanisms associated with immune dysregulation, serum autoantibodies are believed to play a key role in disease progression. Autoantibodies are deposited in the form of apoptotic cell debris and immune complexes, causing inflammation in target organs, including the kidneys.

[0007] According to the above mechanism, patients with lupus develop various immune disorders, including skin rashes and renal abnormalities. The most common and fatal complication is lupus nephritis, a type of glomerulonephritis. The pathophysiology of lupus nephritis involves abnormal immune regulation and renal inflammation, which are significantly exacerbated by autoantibody-associated disorders.

[0008] Meanwhile, Progesterone-Induced Blocking Factor 1 (PIBF1) is a protein induced by exposure to progesterone. PIBF1 is well known to play a crucial role in maintaining immune system balance during pregnancy and functions to regulate the immune response of progesterone. The full-length form of PIBF1 weighs 90 kDa and is reported to be involved in cell cycle regulation.

[0009] However, no specific therapeutic effect of PIBF1 in preventing or treating systemic lupus erythematosus or lupus nephritis has been reported yet.

[0010]

[0011] One object of the present invention is to provide a pharmaceutical composition for preventing or treating systemic lupus erythematosus or lupus nephritis, which contains PIBF1 (Progesterone-Induced Blocking Factor 1) as an active ingredient.

[0012] Another object of the present invention is to provide a food composition for preventing or improving systemic lupus erythematosus or lupus nephritis, which contains PIBF1 as an active ingredient.

[0013] Another object of the present invention is to provide a kit for preventing or treating systemic lupus erythematosus or lupus nephritis, including a composition comprising PIBF1 as an active ingredient and an instruction manual.

[0014] Another object of the present invention is to provide a method for characterizing a responder for a therapeutic agent for treating systemic lupus erythematosus or lupus nephritis, comprising the following steps:

[0015] (S1) a step of measuring the level of CXCL10 (CXC motif chemokine ligand 10) in a blood sample isolated from a subject; and

[0016] (S2) If the level of CXCL10 measured in the above step (S1) is increased compared to the control group, a step of determining the patient as a responder to a treatment for systemic lupus erythematosus or lupus nephritis;

[0017] A method wherein the above treatment comprises PIBF1 as an active ingredient.

[0018] Another object of the present invention is to provide a composition for determining a patient with systemic lupus erythematosus or lupus nephritis in need of administration of the composition, which comprises as an active ingredient a preparation for measuring the level of CXCL10 in blood isolated from a subject.

[0019]

[0020] However, the technical problems to be solved by the present invention are not limited to the problems mentioned above, and other problems not mentioned can be clearly understood by a person having ordinary skill in the technical field to which the present invention belongs from the description below.

[0021]

[0022] The present invention provides a pharmaceutical composition for preventing or treating systemic lupus erythematosus or lupus nephritis, comprising PIBF1 (Progesterone-Induced Blocking Factor 1) as an active ingredient.

[0023] In one embodiment of the present invention, the PIBF1 may be encoded by a nucleic acid sequence represented by SEQ ID NO: 1, but is not limited thereto.

[0024] In one embodiment of the present invention, the composition may be administered by any one method selected from the group consisting of intraperitoneal administration, intravenous administration, and oral administration, but is not limited thereto.

[0025] In one embodiment of the present invention, the composition may be administered twice a week at 20 to 30 μg, but is not limited thereto.

[0026] In one embodiment of the present invention, the composition may be characterized by one or more of the following, but is not limited thereto:

[0027] Decreased anti-dsDNA autoantibodies in serum;

[0028] Decreased urine albumin creatinine ratio (uACR); and

[0029] Increased marginal zone B cells (MZ B cells) and regulatory B cells.

[0030] The present invention provides a food composition for preventing or improving systemic lupus erythematosus or lupus nephritis, comprising PIBF1 as an active ingredient.

[0031] In one embodiment of the present invention, the food may be a health functional food, but is not limited thereto.

[0032] The present invention provides a kit for preventing or treating systemic lupus erythematosus or lupus nephritis, comprising a composition comprising PIBF1 as an active ingredient and an instruction manual.

[0033] The present invention provides a method for characterizing a responder for a therapeutic agent for treating systemic lupus erythematosus or lupus nephritis, comprising the following steps:

[0034] (S1) a step of measuring the level of CXCL10 in a blood sample separated from a subject; and

[0035] (S2) If the level of CXCL10 measured in the above step (S1) is increased compared to the control group, a step of determining the patient as a responder to a treatment for systemic lupus erythematosus or lupus nephritis;

[0036] A method wherein the above treatment comprises PIBF1 as an active ingredient.

[0037] The present invention provides a composition for determining a patient with systemic lupus erythematosus or lupus nephritis in need of administration of the composition, which comprises as an active ingredient a preparation for measuring the level of CXCL10 in blood isolated from a subject.

[0038] In addition, the present invention provides a use of PIBF1 (Progesterone-Induced Blocking Factor 1) or a composition containing it as an active ingredient for preventing, improving, or treating systemic lupus erythematosus or lupus nephritis.

[0039] In addition, the present invention provides a use for manufacturing a preparation for preventing, improving or treating systemic lupus erythematosus or lupus nephritis using PIBF1 (Progesterone-Induced Blocking Factor 1) or a composition containing it as an active ingredient.

[0040] In addition, the present invention provides a method for preventing or treating systemic lupus erythematosus or lupus nephritis, comprising a step of administering PIBF1 (Progesterone-Induced Blocking Factor 1) or a composition containing the same as an active ingredient to a subject in need thereof.

[0041] In addition, the present invention provides a use for characterizing a responder for a therapeutic agent for treating systemic lupus erythematosus or lupus nephritis, comprising PIBF1 (Progesterone-Induced Blocking Factor 1) or a composition containing the same as an active ingredient.

[0042] In addition, the present invention provides a preparation for measuring the level of CXCL10 in blood isolated from a subject or a composition containing the preparation as an active ingredient for use in the diagnosis of a patient with systemic lupus erythematosus or lupus nephritis.

[0043] In addition, the present invention provides a method for determining a patient with systemic lupus erythematosus or lupus nephritis, comprising a step of measuring the level of CXCL10 in blood isolated from a subject using a preparation for measuring the level of CXCL10 in blood isolated from a subject or a composition containing the preparation as an active ingredient.

[0044]

[0045] A pharmaceutical composition for preventing or treating systemic lupus erythematosus containing PIBF1 as an active ingredient confirmed the therapeutic role of PIBF1 in a lupus nephritis-like mouse model. Specifically, PIBF1 showed excellent lupus disease progression alleviation and treatment effects by significantly reducing both serum anti-dsDNA autoantibodies and urine albumin creatinine ratio (uACR). In addition, it was confirmed to have excellent lupus prevention effects by reducing B220+ DNT cells, which are known to increase in a lupus-prone mouse model. Therefore, it is expected to be usefully utilized as a composition for preventing or treating systemic lupus erythematosus and lupus nephritis.

[0046]

[0047] Figure 1 is a schematic diagram showing the experimental design of the lupus mouse model of the present invention.

[0048] Figure 2 is a graph showing the decrease in hormone levels in a group of mice that underwent ovariectomy.

[0049] Figure 3 is a graph showing the effect of increasing the concentration of lupus-related autoantibodies according to PIBF1 treatment.

[0050] Figure 4 is a graph showing the effect of reducing the urine albumin / creatinine ratio according to PIBF1 treatment.

[0051] Figure 5a is a photograph showing the results of staining the kidney of a mouse with H&E, MT, and PAS after PIBF1 treatment.

[0052] Figures 5b and 5c are graphs showing the effect of PIBF1 treatment on reducing renal disease activity and chronicity score.

[0053] Figures 6a to 6f are graphs showing changes in the proportion of CD4-CD8- double negative T cells (DNT cells), B220+ DNT cells, follicular helper T cells (Tfh cells), regulatory B cells (B reg cells), MZ B cells, and CD22- B cells, respectively, according to PIBF1 treatment.

[0054] Figure 7 is a graph showing the inhibitory effect of reducing pro-inflammatory cytokines according to PIBF1 treatment.

[0055] Figure 8 is a graph showing the CXCL10 inhibitory effect according to PIBF1 treatment and the resulting treatment effect on systemic lupus erythematosus and lupus nephritis.

[0056]

[0057] The present invention provides a pharmaceutical composition for preventing or treating systemic lupus erythematosus or lupus nephritis, comprising PIBF1 (Progesterone-Induced Blocking Factor 1) as an active ingredient.

[0058] Hormone binding induces a conformational change in the steroid receptor, allowing DNA binding and gene induction, leading to protein synthesis. Progesterone-induced blocking factor (PIBF) is one of the progesterone-regulated genes, and the resulting protein is responsible for progesterone's immunomodulatory effects.

[0059] The PIBF1 gene, whose transcribed mRNA contains 18 exons, encodes a 90-kDa protein, which is the source of several smaller isoforms. The full-length PIBF and smaller isoforms have distinct functions: the 90-kDa form is associated with the nucleus and may be a component of pericentromeric satellites, whereas the smaller form is localized to the cytoplasm. The former plays a role in cell cycle regulation, whereas the smaller isoform is secreted and can bind to glycosylphosphatidylinositol (GPI)-anchored PIBF receptors.

[0060] In the present invention, PIBF1 may be a recombinant protein in which FC is combined with PIBF for drug optimization such as half-life extension and stabilization, and may be recombined with not only FC but also albumin, albumin binding protein, IgG, PEGylation, etc., but is not limited thereto.

[0061] Additionally, in the present invention, the PIBF1 protein may be described as PIBF1, and both words may be used interchangeably.

[0062] Additionally, the PIBF1 protein may have a molecular weight of 25 to 45 kDa, preferably a molecular weight of 30 to 40 kDa, and more preferably a molecular weight of 35 kDa.

[0063] In the present invention, PIBF1 may be a recombinant protein, and may be in a 35 kDa total secretory form. “TTGGCCGCGTCGGCCGCTAGC” in SEQ ID NO: 1 of the present invention and “Leu Ala Ala Ser Ala Ala Ser” in SEQ ID NO: 2 may refer to a linker between the 35 kDa total PIBF and the Fc tag. The PIBF1 recombinant protein of the present invention may have an Fc tag attached to enhance stability, thereby further enhancing the efficacy in preventing or treating systemic lupus erythematosus or lupus nephritis, but is not limited thereto.

[0064] In one embodiment of the present invention, the PIBF1 may be encoded by a nucleic acid sequence represented by SEQ ID NO: 1, but is not limited thereto.

[0065] Additionally, the PIBF1 protein may be encoded by a nucleic acid sequence represented by SEQ ID NO: 1, may include an amino acid sequence represented by SEQ ID NO: 2, or may be represented by SEQ ID NO: 2, but is not limited thereto.

[0066] Additionally, the terms “percent identity,” “sequence identity,” “percent similarity,” “sequence similarity,” “percent sequence identity,” and the like, as used herein with respect to amino acid sequences and / or nucleic acid sequences in the present invention, may refer to, but are not limited to, a measure determined by comparing the degree of similarity of two sequences based on alignment of the sequences that maximizes the similarity between aligned amino acid residues or nucleotides and is a function of the number of identical or similar residues or nucleotides, the total number of residues or nucleotides, and the presence and length of gaps in the sequence alignment.

[0067] Portions of a polynucleotide or polypeptide sequence may contain additions or deletions (i.e., gaps) compared to a reference sequence (which does not contain additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the same nucleic acid base or amino acid residue appears in both sequences to yield the number of matching positions, dividing the number of matching positions by the total number of positions in the comparison window, and multiplying the result by 100 to yield the percent sequence identity.

[0068] The term “identical” or percent “identity” in relation to two or more nucleic acid or polypeptide sequences refers to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 60% identity, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or represented region) as measured using the BLAST or BLAST 2.0 sequence comparison algorithms using the default parameters described below or by manual alignment and visual inspection (see, e.g., the NCBI website at http: / / www.ncbi.nlm.nih.gov / BLAST / ). These sequences are then referred to as “substantially identical.”

[0069] This definition also refers to, or can be applied to, complementation of a test sequence. This definition also encompasses sequences with deletions and / or additions, as well as substitutions. As described below, preferred algorithms can account for gaps, etc. Preferably, identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably, over a region that is 50 to 100 amino acids or nucleotides in length.

[0070] Amino acid or nucleotide base “positions” are represented by numbers that sequentially identify each amino acid (or nucleotide base) in the reference sequence based on its position relative to the N-terminus (or 5'-end). Due to deletions, insertions, truncations, fusions, etc., which must be considered when determining optimal alignment, the number of amino acid residues in a test sequence, generally determined simply by counting from the N-terminus, will not necessarily be identical to the number of corresponding positions in the reference sequence. For example, if a variant has a deletion relative to the aligned reference sequence, the amino acid corresponding to the position in the reference sequence at the deletion site will be absent in the variant. If there is an insertion in the aligned reference sequence, the insertion will not correspond to an amino acid position numbered in the reference sequence. In the case of truncations or fusions, there may be a stretch of amino acids in either the reference or aligned sequence that does not correspond to any amino acid in the corresponding sequence.

[0071] The terms “numbered with respect to” or “corresponding to” when used in reference to the numbering of a given amino acid or polynucleotide sequence refers to the numbering of residues in the reference sequence specified when the given amino acid or polynucleotide sequence is compared to the reference sequence.

[0072] In one embodiment of the present invention, the composition may be administered by any one method selected from the group consisting of intraperitoneal administration, intravenous administration, and oral administration, but is not limited thereto.

[0073] In one embodiment of the present invention, the composition may be administered twice a week at 20 to 30 μg, but is not limited thereto.

[0074] In one embodiment of the present invention, the composition may be characterized by one or more of the following, but is not limited thereto:

[0075] Decreased anti-dsDNA autoantibodies in serum;

[0076] Decreased urine albumin creatinine ratio (uACR); and

[0077] Increased marginal zone B cells (MZ B cells) and regulatory B cells.

[0078] In the present invention, systemic lupus erythematosus can be expressed identically to lupus.

[0079] The composition of the present invention has been confirmed through specific data to exhibit not only a therapeutic effect on lupus, but also an effect of alleviating and improving the symptoms of lupus nephritis, the most representative complication of lupus. Therefore, the composition of the present invention can prevent or be effective not only on lupus nephritis, but also on complications arising from lupus nephritis. In addition, the above “treatment” may include alleviating or improving the progression of lupus or lupus nephritis.

[0080] The "pharmaceutical composition" according to the present invention may further include suitable carriers, excipients, and diluents commonly used in the manufacture of pharmaceutical compositions. The excipients may be, for example, one or more selected from the group consisting of diluents, binders, disintegrants, lubricants, adsorbents, moisturizers, film-coating materials, and controlled-release additives.

[0081] The pharmaceutical composition according to the present invention may be formulated and used in the form of external preparations such as powders, granules, sustained-release granules, enteric-coated granules, liquids, eye drops, ellipsoids, emulsions, suspensions, alcohols, troches, aromatic waters, limonades, tablets, sustained-release tablets, enteric-coated tablets, sublingual tablets, hard capsules, soft capsules, sustained-release capsules, enteric capsules, pills, tinctures, soft extracts, dry extracts, fluid extracts, injections, capsules, irrigation solutions, ointments, lotions, pastes, sprays, inhalants, patches, sterile injection solutions, or aerosols, according to a conventional method, and the external preparations may have formulations such as creams, gels, patches, sprays, ointments, ointments, lotions, liniments, pastes, or cataplasmas.

[0082] Carriers, excipients and diluents that may be included in the pharmaceutical composition according to the present invention include lactose, dextrose, sucrose, oligosaccharides, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

[0083] When formulating, it is usually prepared using diluents or excipients such as fillers, bulking agents, binders, wetting agents, disintegrants, and surfactants.

[0084] The additives of the tablets, powders, granules, capsules, pills, and troches according to the present invention include excipients such as corn starch, potato starch, wheat starch, lactose, sucrose, glucose, fructose, D-mannitol, precipitated calcium carbonate, synthetic aluminum silicate, calcium hydrogen phosphate, calcium sulfate, sodium chloride, sodium bicarbonate, purified lanolin, microcrystalline cellulose, dextrin, sodium alginate, methylcellulose, sodium carboxymethylcellulose, kaolin, urea, colloidal silica gel, hydroxypropyl starch, hydroxypropyl methylcellulose (HPMC) 1928, HPMC 2208, HPMC 2906, HPMC 2910, propylene glycol, casein, calcium lactate, and Primogel; Gelatin, gum arabic, ethanol, agar powder, cellulose acetate phthalate, carboxymethylcellulose, calcium carboxymethylcellulose, glucose, purified water, sodium caseinate, glycerin, stearic acid, sodium carboxymethylcellulose, sodium methylcellulose, methylcellulose, microcrystalline cellulose, dextrin, hydroxycellulose, hydroxypropyl starch, hydroxymethylcellulose, refined shellac, starch starch, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinyl alcohol, polyvinyl pyrrolidone, and binders such as hydroxypropyl methylcellulose, corn starch, agar powder, methylcellulose, bentonite, hydroxypropyl starch, sodium carboxymethylcellulose, sodium alginate, Disintegrants such as carboxymethylcellulose calcium, calcium citrate, sodium lauryl sulfate, anhydrous silicic acid, 1-hydroxypropyl cellulose, dextran, ion exchange resin, polyvinyl acetate, formaldehyde-treated casein and gelatin, alginic acid, amylose, guar gum, baking soda, polyvinylpyrrolidone, calcium phosphate, gelled starch, gum arabic, amylopectin, pectin, sodium polyphosphate, ethylcellulose, sucrose, magnesium aluminum silicate, di-sorbitol solution, and light anhydrous silicic acid;Lubricants such as calcium stearate, magnesium stearate, stearic acid, hydrogenated vegetable oil, talc, lycopodium dentata, kaolin, petrolatum, sodium stearate, cocoa butter, sodium salicylate, magnesium salicylate, polyethylene glycol 4000, PEG 6000, liquid paraffin, hydrogenated soybean oil (Lubri wax), aluminum stearate, zinc stearate, sodium lauryl sulfate, magnesium oxide, macrogol, synthetic aluminum silicate, anhydrous silicic acid, higher fatty acids, higher alcohols, silicone oil, paraffin oil, polyethylene glycol fatty acid ether, starch, sodium chloride, sodium acetate, sodium oleate, dl-leucine, and light anhydrous silicic acid can be used.;

[0085] As additives of the liquid formulation according to the present invention, water, dilute hydrochloric acid, dilute sulfuric acid, sodium citrate, monostearate sucrose, polyoxyethylene sorbitol fatty acid esters (twin esters), polyoxyethylene monoalkyl ethers, lanolin ethers, lanolin esters, acetic acid, hydrochloric acid, ammonia water, ammonium carbonate, potassium hydroxide, sodium hydroxide, prolamine, polyvinylpyrrolidone, ethylcellulose, sodium carboxymethylcellulose, etc. can be used.

[0086] The syrup according to the present invention may include a solution of white sugar, other sugars, or sweeteners, and may also include a fragrance, a coloring agent, a preservative, a stabilizer, a suspending agent, an emulsifier, a viscosity modifier, and the like, as needed.

[0087] Purified water may be used in the emulsion according to the present invention, and emulsifiers, preservatives, stabilizers, fragrances, etc. may be used as needed.

[0088] The suspension according to the present invention may include suspending agents such as acacia, tragacanth, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, microcrystalline cellulose, sodium alginate, hydroxypropylmethylcellulose, HPMC 1828, HPMC 2906, and HPMC 2910, and, if necessary, surfactants, preservatives, stabilizers, colorants, and fragrances may be used.

[0089] The injection according to the present invention includes a solvent such as distilled water for injection, 0.9% sodium chloride injection, Ringer's injection, dextrose injection, dextrose + sodium chloride injection, PEG, lactated Ringer's injection, ethanol, propylene glycol, non-volatile oils - sesame oil, cottonseed oil, peanut oil, soybean oil, corn oil, ethyl oleate, isopropyl myristate, and benzene benzoate; a solubilizing agent such as sodium benzoate, sodium salicylate, sodium acetate, urea, urethane, monoethylacetamide, butazolidine, propylene glycol, tween, nitrile acid amide, hexamine, and dimethylacetamide; a buffer such as weak acids and their salts (acetic acid and sodium acetate), weak bases and their salts (ammonia and ammonium acetate), organic compounds, proteins, albumin, peptone, and gums; It may include isotonic agents such as sodium chloride; stabilizers such as sodium bisulfite (NaHSO3), carbon dioxide gas, sodium metabisulfite (Na2S2O5), sodium sulfite (Na2SO3), nitrogen gas (N2), and ethylenediaminetetraacetic acid; oxidizing agents such as sodium bisulfite 0.1%, sodium formaldehyde sulfoxylate, thiourea, disodium ethylenediaminetetraacetic acid, and acetone sodium bisulfite; analgesics such as benzyl alcohol, chlorobutanol, procaine hydrochloride, glucose, and calcium gluconate; and suspending agents such as sodium cis-methylenediamine, sodium alginate, Tween 80, and aluminum monostearate.

[0090] The suppository according to the present invention comprises cocoa butter, lanolin, withepsol, polyethylene glycol, glycerogelatin, methylcellulose, carboxymethylcellulose, a mixture of stearic acid and oleic acid, Subanal, cottonseed oil, peanut oil, palm oil, cocoa butter + cholesterol, lecithin, ranet wax, glycerol monostearate, Tween or Span, Imhausen, monolene (propylene glycol monostearate), glycerin, Adeps solidus, Buytyrum Tego-G, Cebes Pharma 16, hexalide base 95, Cotomar, Hydroxocote SP, S-70-XXA, S-70-XX75 (S-70-XX95), Mechanisms such as Hydrokote 25, Hydrokote 711, Idropostal, Massa estrarium (A, AS, B, C, D, E, I, T), Massa-MF, Masupol, Masupol-15, Neosupostal-N, Paramound-B, Suposiro (OSI, OSIX, A, B, C, D, H, L), Suppository type IV (AB, B, A, BC, BBG, E, BGF, C, D, 299), Supostal (N, Es), Wecovi (W, R, S, M, Fs), and Tezester triglyceride basis (TG-95, MA, 57) can be used.

[0091] Solid dosage forms for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid dosage forms are prepared by mixing the extract with at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.

[0092] Liquid preparations for oral administration include suspensions, solutions, emulsions, and syrups. In addition to commonly used simple diluents such as water and liquid paraffin, they may contain various excipients such as wetting agents, sweeteners, flavoring agents, and preservatives. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions can include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.

[0093] The pharmaceutical composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment. The effective dosage level can be determined based on factors including the type and severity of the patient's disease, drug activity, drug sensitivity, administration time, administration route and excretion rate, treatment period, concurrently used drugs, and other factors well known in the medical field.

[0094] The pharmaceutical composition according to the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents. It can be administered sequentially or simultaneously with conventional therapeutic agents, or in single or multiple doses. Taking all of the above factors into account, it is important to administer an amount that achieves maximum efficacy with minimal side effects. This amount can be readily determined by those skilled in the art to which the present invention pertains.

[0095] The pharmaceutical composition of the present invention can be administered to a subject via various routes. All modes of administration are conceivable, including oral ingestion, subcutaneous injection, intraperitoneal administration, intravenous injection, intramuscular injection, intrathecal injection, sublingual administration, buccal mucosal administration, rectal insertion, vaginal insertion, ocular administration, otic administration, nasal administration, inhalation, oral or nasal spraying, dermal administration, and transdermal administration.

[0096] The pharmaceutical composition of the present invention is determined according to the type of drug as an active ingredient, along with various related factors such as the disease to be treated, the route of administration, the patient's age, sex, weight, and the severity of the disease. Specifically, the effective dose of the composition according to the present invention may vary depending on the patient's age, sex, and weight, and is generally 0.001 to 150 mg per 1 kg of body weight, preferably 0.01 to 100 mg, administered daily or every other day, or divided into 1 to 3 times a day. However, since the dosage may increase or decrease depending on the route of administration, the severity of the disease, sex, weight, age, etc., the above dosage does not limit the scope of the present invention in any way.

[0097] In the present invention, “subject” means a subject requiring treatment for a disease, and more specifically, means a mammal such as a human or non-human primate, mouse, rat, dog, cat, horse, and cow.

[0098] In the present invention, “administration” means providing a predetermined composition of the present invention to a subject by any suitable method. In the present invention, “prevention” means any action that inhibits or delays the onset of a target disease, “treatment” means any action that improves or beneficially changes a target disease and its resulting metabolic abnormality symptoms by administering a pharmaceutical composition according to the present invention, and “improvement” means any action that reduces a parameter related to a target disease, for example, the severity of a symptom, by administering a composition according to the present invention.

[0099] The present invention provides a food composition for preventing or improving systemic lupus erythematosus or lupus nephritis, comprising PIBF1 as an active ingredient.

[0100] In one embodiment of the present invention, the food may be a health functional food, but is not limited thereto. The health functional food may have the advantage of having even better effects when consumed in the form of an inner beauty food. The inner beauty is referred to as an "edible cosmetic or beauty food," and refers to a food that changes the skin constitution to a healthy one by allowing the body to absorb various skin-friendly ingredients. Just as one selects cosmetics that suit one's skin type, one can select and consume inner beauty foods that suit one's skin condition and lifestyle. For example, when cosmetics and inner beauty foods are combined, the effect is significantly enhanced compared to using cosmetics or medications alone, and thus, it can have the advantage of having a more effective skin condition improvement effect.

[0101] When using the above-mentioned active ingredient as a food additive, it can be added directly or combined with other foods or food ingredients, and can be used appropriately according to conventional methods. The amount of active ingredient mixed can be appropriately determined depending on the intended use (prevention, health, or therapeutic treatment).

[0102] There are no specific restrictions on the types of the above foods. Examples of foods to which the above substances can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, and all health functional foods in the conventional sense are included.

[0103] The health beverage composition according to the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients, similar to conventional beverages. The natural carbohydrates mentioned above include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As a sweetener, natural sweeteners such as thaumatin and stevia extract, or synthetic sweeteners such as saccharin and aspartame may be used. The proportion of the natural carbohydrate is generally about 0.01-0.20 g or about 0.04-0.10 g per 100 mL of the composition of the present invention.

[0104] In addition to the above, the composition of the present invention may contain various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. In addition, the composition of the present invention may contain fruit pulp for the production of natural fruit juice, fruit juice drinks, and vegetable drinks. These ingredients may be used independently or in combination. The proportion of these additives is not particularly critical, but is typically selected within the range of 0.01 to 0.20 parts by weight per 100 parts by weight of the composition of the present invention.

[0105] The present invention provides a kit for preventing or treating systemic lupus erythematosus or lupus nephritis, comprising a composition comprising PIBF1 as an active ingredient and an instruction manual.

[0106] In addition to the above components, the “kit” of the present invention may include other components, devices, materials, etc. that are typically necessary for enhancing the therapeutic effect of the composition of the present invention on lupus or lupus nephritis, or for a method for storing or managing the composition of the present invention. In addition, all components included in the kit may be used at least once without limitation on the number of times, there is no limitation on the order in which each substance is used, and the application of each substance may be performed simultaneously or microscopically.

[0107] The kit of the present invention may include a container in addition to the formulation and instructions. The container may serve to package the composition, and may also serve to store and secure the composition. The container may be formed of a material such as a bottle, a tub, a sachet, an envelope, a tube, an ampoule, or the like, and may be formed partially or wholly from plastic, glass, paper, foil, wax, or the like. The container may be equipped with a completely or partially detachable stopper, which may initially be part of the container or may be attached to the container by mechanical, adhesive, or other means, and may also be equipped with a stopper that allows access to the contents by means of a syringe needle. The kit may include an outer package, which may include, but is not limited to, instructions for the use of the components.

[0108] The present invention provides a method for characterizing a responder for a therapeutic agent for treating systemic lupus erythematosus or lupus nephritis, comprising the following steps:

[0109] (S1) a step of measuring the level of CXCL10 in a blood sample separated from a subject; and

[0110] (S2) If the level of CXCL10 measured in the above step (S1) is increased compared to the control group, a step of determining the patient as a responder to a treatment for systemic lupus erythematosus or lupus nephritis;

[0111] A method wherein the above treatment comprises PIBF1 as an active ingredient.

[0112] The present invention provides a composition for determining a patient with systemic lupus erythematosus or lupus nephritis in need of administration of the composition, which comprises as an active ingredient a preparation for measuring the level of CXCL10 in blood isolated from a subject.

[0113] In the present invention, “companion diagnostic” may refer to one of the diagnostic tests for confirming the possibility of applying a specific therapeutic drug (including a targeted therapeutic agent) to a specific patient. That is, according to the present invention, since the level of CXCL10 in a blood sample isolated from a subject or a formulation for measuring the same can be used as a method and composition for applying a composition comprising PIBF1 of the present invention as an active ingredient to a patient with lupus or lupus nephritis, CXCL10 may be referred to as a companion diagnostic marker for lupus or lupus nephritis.

[0114] In the present invention, "discrimination" may mean distinguishing a subject based on a specific criterion. For example, in the present invention, if the level of CXCL10 is higher than that of the control group, it may be used to distinguish whether or not a subject has drug resistance to the composition of the present invention containing PIBF1 as an active ingredient, or whether or not a subject has sensitivity to the composition of the present invention.

[0115] In the present invention, "targeted therapeutic agent" may include any therapeutic agent targeting a specific disease. In the present invention, it may refer to the PIBF1 protein, but is not limited thereto.

[0116] In the present invention, "resistance," also referred to as "tolerance," refers to the absence of a significant cellular or biological response to a specific drug. Specifically, it may refer to, but is not limited to, the absence or reduction in the rate of cell death or apoptosis associated with lupus or lupus nephritis in response to drug treatment.

[0117] In addition, in the present invention, the “need for administration” refers to determining whether to administer the therapeutic agent (drug) to an individual who can or is expected to obtain a therapeutic effect from the therapeutic agent (drug), and the determination can be performed by measuring the copy number or expression level of the companion diagnostic marker of the present invention and comparing it with a reference value.

[0118] Additionally, in the present invention, the term “control group” may mean an individual who may not be diagnosed with the disease, and in the present invention, may mean an individual who is not diagnosed with lupus or lupus nephritis.

[0119] In addition, the present invention provides a use of PIBF1 or a composition containing it as an active ingredient for preventing, improving or treating systemic lupus erythematosus or lupus nephritis.

[0120] In addition, the present invention provides a use for manufacturing a preparation for preventing, improving or treating systemic lupus erythematosus or lupus nephritis using PIBF1 or a composition containing it as an active ingredient.

[0121] In addition, the present invention provides a method for preventing or treating systemic lupus erythematosus or lupus nephritis, comprising a step of administering PIBF1 or a composition containing it as an active ingredient to a subject in need thereof.

[0122] The present invention also provides a use for characterizing responders for a therapeutic agent for treating systemic lupus erythematosus or lupus nephritis, comprising PIBF1 or a composition comprising the same as an active ingredient.

[0123]

[0124] Hereinafter, preferred examples are presented to aid in understanding the present invention. However, the following examples are provided solely to facilitate a better understanding of the present invention, and the scope of the present invention is not limited by the following examples.

[0125]

[0126] [Example]

[0127]

[0128] Construction of the murine model

[0129] All mice were bred and maintained under specific pathogen-free conditions. Mice were subdivided into three groups, as shown in Figure 1. Specifically, female MRL / MpJ-Fas mice, which are prone to lupus lpr / J (MRL / lpr) mice were ovariectomized at 6 weeks of age (n=18). Half of the ovariectomized mice were treated with PIBF1 (MRL / lpr+OVX-PIBF1) from 8 to 26 weeks of age, and the other half with PBS (control; MRL / lpr+OVX-PBS). Female MRL / MpJ mice served as negative controls. Blood sampling was performed every 2 weeks, and urine sampling was performed at the end (26 weeks) in all groups. All mouse experiments were performed in accordance with the animal experiment guidelines approved by the Institutional Animal Care and Use Ethics Committee of the Life Science Research Institute, Asan Medical Center, Seoul. For PIBF1 administration, the 35-kDa secreted form of PIBF1 was injected intraperitoneally (25 μg / animal / twice a week). PIBF1 was donated by Professor Yoo-Sook Cho (Department of Allergy and Clinical Immunology, Asan Medical Center, College of Medicine, University of Ulsan).

[0130]

[0131]

[0132]

[0133] Flow Cytometry Analysis

[0134] Spleens were collected, lysed in PBS through a 70 μm filter, and centrifuged at 350 × g for 5 min. The pellet was resuspended in PBS and centrifuged again. The pellet was resuspended in red blood cell lysis buffer (BioLegend, USA) to remove red blood cells, and the lysis reaction was stopped by adding PBS. The pellet was washed with PBS to obtain a single spleen cell suspension. After single cell preparation, Fc receptors were blocked with anti-mouse-CD16 / 32 (clone: ​​93, BioLegend), and spleen and kidney cells were stained with cell surface markers anti-CD3-PE / Cy7 (clone: ​​17A2, BioLegend), anti-CD4-PerCP / Cy5.5 (clone: ​​GK1.5, BioLegend), anti-CD8-FITC (clone: ​​5H10-1, BioLegend), anti-B220-APC (clone: ​​RA3-6B2, BioLegend), anti-CXCR5-BV421 (clone: ​​L138D7, BioLegend), anti-CD5-APC / Cy7 (clone: ​​53-7. 3, BioLegend), anti-CD1d-BV421 (clone: ​​1B1, BioLegend), anti-CD22-FITC (clone: The cells were stained with OX-97 (BioLegend).

[0135]

[0136] Enzyme-Linked Immunosorbent Assay (ELISA)

[0137] Estradiol (17-beta Estradiol ELISA Kit, Abcam, UK) and progesterone levels (Immuno-Biological Laboratories, USA) were also detected using ELISA kits. All analytical procedures were performed according to the manufacturer's instructions. Serum anti-dsDNA antibody levels were measured using an ELISA kit (Mouse Anti-dsDNA Antibodies Total Ig, ALPHA DIAGNOSIC INTERNATIONAL, USA) according to the manufacturer's instructions. Specifically, diluted plasma was added to the dsDNA immobilized on the plate, incubated for 1 hour at RT, and washed four times. The wells were then incubated with HRP-conjugated anti-mouse Ig for 30 minutes and washed five times. After washing, a chromogenic substrate (TMB) was added for color development, and the reaction was terminated by adding stop solution. The absorbance of each well was measured at a wavelength of 450 nm. Creatinine levels were measured using the Creatinine Colorimetric Detection Kit (Enzo Life Sciences, USA). Diluted urine and creatinine detection reagent were added to each well and incubated at room temperature for 30 minutes. Optical density was observed at a wavelength of 490 nm. Urine albumin concentration was measured using an ELISA (Mouse Albumin ELISA Kit, Abcam, UK). Diluted samples were added to the wells, incubated for 2 hours, and then washed five times. Biotinylated albumin antibody was added, incubated for 1 hour, and then washed five times. Streptavidin-peroxidase conjugate was added, incubated for 30 minutes, and then washed five times. Chromogenic substrate (TMB) was added until the optimal color intensity was achieved and the reaction was terminated with stop solution. Absorbance was measured at a wavelength of 450 nm.

[0138]

[0139] Kidney Histology Examinations

[0140] Before kidney isolation, mice were anesthetized and transcardially perfused with PBS. Kidneys were fixed in 10% neutral buffered formalin for histological examination. After fixation, organs were embedded in paraffin and sectioned into 4-μm-thick slices. Sections were then stained with hematoxylin and eosin (H&E), Masson's trichome (MT), and periodic acid-Schiff (PAS).

[0141] Pathologic features of renal histology were evaluated using a semiquantitative grading system. Disease activity indicators such as intracapillary hypercellularity, neutrophil lysis, glomerular capillary loops, fibrinoid necrosis, hyaline deposition, and interstitial inflammation were assessed. An overall disease activity score was calculated as the sum of these indicators. Chronicity indicators included the total percentage of glomerular sclerosis and interstitial fibrosis. A chronicity score was further calculated as the sum of these indicators. Disease severity was assessed on a 0- to 3-point scale based on the glomerular percentage of each indicator, with 0 = no glomeruli, 1 = <25% glomeruli, 2 = 25-50% glomeruli, and 3 = ≥50% glomeruli. The criteria for this grading system were adopted from “Bajema, IM, et al., Revision of the International Society of Nephrology / Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int, 2018. 93(4): p. 789-796.”

[0142]

[0143]

[0144]

[0145] Serum Cytokine Analysis by Luminex Multiplex Cytokine Assay

[0146] Serum samples were prepared from all mouse groups at 16 (n=33) and 24 (n=29) weeks of age. Cytokines were analyzed using the Luminex Multiplex cytokine assay. Blood was allowed to clot for 1 h at RT and then centrifuged at 10,000 × g for 10 min at 4°C. Serum concentrations of the following cytokines were measured using a Magnetic Bead-based 7-plex immunoassay: IFN-γ, IL-2, IL-6, IL-10, IL-12 (IL-12 p70), and IL-21 (Procreate Mouse custom plex, Thermo-Scientific).

[0147] Specifically, the standards were diluted fourfold serially. Serum samples and diluted standards were combined with antibody-conjugated magnetic beads and incubated for 2 h at RT on a 500 rpm shaker. After washing, the plates were incubated with detection antibodies for 30 min at RT. After three washes, the plates were resuspended in streptavidin-PE and incubated for 30 min at RT. Three additional washes were performed and the plates were resuspended in reading buffer. Each sample was measured along with standards (fourfold serial, seven-point dilutions) and buffer controls. The plates were read for quantitative analysis using a Luminex Bio-plex 200 system (Bio-Rad Corporation, USA).

[0148]

[0149] Statistical Analysis

[0150] All statistical analyses were performed using GraphPad Prism 8 (GraphPad Software, San Diego, USA). Comparisons between groups were performed using the Mann-Whitney test. All data are expressed as mean ± SEM. A P value less than 0.05 was considered significant.

[0151]

[0152] Example 1. Confirmation of decreased estradiol and progesterone levels in ovariectomized rats.

[0153] Serum estradiol and progesterone levels were measured by ELISA to confirm that the ovariectomy was performed correctly.

[0154]

[0155] As a result, the levels of both hormones were found to be significantly decreased in the group that underwent oophorectomy (Fig. 2). Specifically, estradiol concentrations were found to be significantly decreased at 12 weeks of age, and progesterone levels were found to be significantly decreased at 8 weeks of age in the oophorectomy group (OVX; n=18) compared to the non-oophorectomy group (Non-OVX; n=10).

[0156]

[0157] Example 2. Confirmation of the inhibitory effect of PIBF1 on the increase in autoantibody concentration.

[0158] One of the most characteristic features of lupus is the level of anti-dsDNA autoantibodies in the blood. Therefore, to evaluate the role of PIBF1 in lupus progression, we measured anti-dsDNA autoantibody levels in the serum of mice every two weeks.

[0159]

[0160] As a result, the anti-dsDNA level in the MRL / lpr+OVX-PBS group was found to gradually increase from the 14th week. In contrast, the autoantibody level in the PIBF1 treatment group did not increase after the 18th week of life and showed a tendency to decrease somewhat thereafter (Fig. 3).

[0161]

[0162] Example 3. Confirmation of the effect of PIBF1 on reducing the urine albumin / creatinine ratio.

[0163] The most common complication of lupus is lupus nephritis. Therefore, to confirm the development of renal disease in a lupus mouse model, we analyzed the urine albumin / creatinine ratio (uACR), a key indicator of renal failure and lupus nephritis. Specifically, the uACR was measured in the urine of 26-week-old mice in all groups using ELISA.

[0164]

[0165] As a result, the uACR values ​​of both OVX groups were significantly higher than those of the MRL / MpJ group. However, the OVX group treated with PIBF1 showed a significant decrease in uACR compared to the OVX group not treated with PIBF1, and this was statistically significant, demonstrating the therapeutic effect of PIBF1 on lupus and lupus nephritis (Fig. 4).

[0166]

[0167] Example 4. Confirmation of the effect of PIBF1 on reducing disease activity and chronicity score in the kidney.

[0168] To determine the role of PIBF1 in lupus, renal biopsies were performed to analyze the increase or decrease in renal disease activity and chronicity scores. Disease activity and chronicity scores were scored according to criteria published by the National Institutes of Health (NIH) (Tables 2 and 3). After sacrifice at 26 weeks of age, kidney specimens were prepared and stained with hematoxylin and eosin (H&E), Masson's trichomatis (MT), and periodic acid-Schiff (PAS) stains (Figure 5a). Disease activity markers included capillary hypercellularity, neutrophil lysis, hyaline deposition, cellular crescents, fibrinous necrosis, and interstitial inflammation. Each index represents inflammatory cell influx, neutrophil apoptosis, subendothelial deposits (i.e., immune complexes), and lesions. Fibrinous necrosis is known to be a marker of lupus nephritis development. Chronicity indices include glomerulosclerosis, fibrous crescents, tubular atrophy, and interstitial fibrosis. Glomerulosclerosis indicates complete hardening of the glomeruli and is a hallmark of lupus nephritis. Tubular atrophy and interstitial fibrosis can be considered interstitial infiltrates.

[0169]

[0170]

[0171]

[0172]

[0173] Overall, this study demonstrated the therapeutic role of PIBF1 in the kidneys of MRL / lpr mice through histological examination. Specifically, PIBF1 was found to alleviate lupus disease progression and reduce overall kidney activity and chronicity scores. Notably, among these disease-related indices, interstitial inflammation and systemic glomerulosclerosis were reduced after PIBF1 treatment. Both indices were associated with renal tubular dysfunction and glomerulosclerosis, which may be signs of proteinuria. Therefore, investigating the effect of PIBF1 on renal tubular cells may be considered a clue to approaching how PIBF1 exerts its anti-inflammatory effects in lupus nephritis. Several disease-related parameters, including neutrophil lysis, fibrinonecrosis, and parameters related to interstitial inflammation, were increased in MRL / lpr mice, whereas they were barely observed in the MRL / MpJ group (negative control). The overall disease activity score, including interstitial inflammation, was significantly reduced compared to the PIBF1-untreated group (Fig. 5b). Furthermore, with regard to disease chronicity indices, both the overall glomerulosclerosis score and the total chronicity score were reduced in the ovariectomized group treated with PIBF1 (Fig. 5c).

[0174]

[0175] Example 5. Confirmation of the therapeutic effect of PIBF1 on systemic lupus erythematosus according to various indicators in spleen cells.

[0176] To confirm the therapeutic effect of PIBF1 on systemic lupus erythematosus, spleen cells from all mouse groups at 26 weeks of age were analyzed using flow cytometry analysis using the method described in 'Flow Cytometry Analysis' described above.

[0177]

[0178] As a result, T cells and CD4 in the spleen cells of whole MRL / lpr mice - CD8 -While the proportion of double-negative T cells (DNT cells) increased, no statistical difference was found between the OVX-PBS and OVX-PIBF1 groups (Fig. 6a). B220 + T cells showed a similar trend. However, in the PIBF1-treated group, B220 + DNT cells were reduced (Fig. 6b).

[0179] Follicular helper T cells (Tfh cells) increased in MRL / lpr mice, but no statistically significant difference was found between the two ovariectomized groups (Fig. 6c). B reg cells and MZ B cells, which are thought to perform a clearing function for apoptotic debris, decreased in the MRL / lpr group (Figs. 6d and 6e), whereas CD22-deficient B cells increased (Fig. 6f). CD22 is also known as an inhibitor of BCR signaling. CD22 deficiency induces B cell hypersensitivity, leading to autoantibody production, and this trend was different after PIBF1 treatment.

[0180]

[0181] Example 6. Confirmation of the inhibitory effect of PIBF1 on reducing proinflammatory cytokines.

[0182] We measured serum cytokine levels known to be associated with lupus pathophysiology or the immunoregulatory function of PIBF1. Specifically, serum samples were prepared from 16- and 24-week-old mice and cytokine changes following PIBF1 treatment were examined.

[0183]

[0184] As a result, the levels of proinflammatory cytokines IFN-r, IL-6, and IL-12 were significantly elevated in all MRL / lpr mice. However, no statistically significant differences were found between the ovariectomized groups (Fig. 7).

[0185]

[0186] Example 7. Confirmation of CXCL10 inhibition effect by PIBF1

[0187] The CXCL10 inhibitory effect of PIBF was confirmed using the MRL / MpJ-Faslpr / J mouse model, which spontaneously develops lupus symptoms. Specifically, the experimental groups were set up as four groups: wild-type MRL / MpJ, mutant MRL / MpJ-Faslpr / J, MRL / MpJ-Faslpr / J + ovariectomy, and MRL / MpJ-Faslpr / J + ovariectomy + PIBF treatment. After ovariectomy in 6-week-old MRL / MpJ-Faslpr / J mice, PIBF was intraperitoneally treated twice per week starting at 8 weeks of age. Then, orbital blood samples were collected from 10-, 16-, and 24-week-old mice, and the serum was separated to measure the concentration of CXCL10.

[0188]

[0189] As a result, the concentration of CXCL10 was significantly reduced in the PIBF-treated mice group after ovariectomy at 16 and 24 weeks of age compared to the ovariectomized control group (Fig. 8). According to these results, PIBF was confirmed to delay the onset of lupus and suppress the development of nephritis through CXCL10 inhibition.

[0190]

[0191] The foregoing description of the present invention is provided for illustrative purposes only. Those skilled in the art will readily appreciate that the present invention can be readily modified into other specific forms without altering the technical spirit or essential characteristics of the present invention. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive.

[0192]

[0193] The pharmaceutical composition for preventing or treating systemic lupus erythematosus, which comprises PIBF1 as an active ingredient according to the present invention, specifically shows an excellent lupus disease progression alleviation and treatment effect by significantly reducing both anti-dsDNA autoantibodies in serum and urine albumin creatinine ratio (uACR), and also shows an excellent lupus prevention effect by reducing B220+ DNT cells, which are known to increase in a mouse model susceptible to lupus. Therefore, the composition can be usefully used as a composition for preventing or treating lupus and lupus nephritis, and thus has industrial applicability.

Claims

1. A pharmaceutical composition for preventing or treating systemic lupus erythematosus or lupus nephritis, comprising PIBF1 (Progesterone-Induced Blocking Factor 1) as an active ingredient.

2. In paragraph 1, A pharmaceutical composition wherein the above PIBF1 is encoded by a nucleic acid sequence represented by sequence number 1.

3. In paragraph 1, A pharmaceutical composition, wherein the composition is administered by any one method selected from the group consisting of intraperitoneal administration, intravenous administration, and oral administration.

4. In paragraph 1, A pharmaceutical composition, wherein the composition is administered twice a week at 20 to 30 μg.

5. In paragraph 1, A pharmaceutical composition characterized by one or more of the following: Decreased anti-dsDNA autoantibodies in serum; Decreased urine albumin creatinine ratio (uACR); and Increased marginal zone B cells (MZ B cells) and regulatory B cells.

6. A food composition for preventing or improving systemic lupus erythematosus or lupus nephritis, comprising PIBF1 as an active ingredient.

7. In paragraph 6, A food composition wherein the above food is a health functional food.

8. A kit for preventing or treating systemic lupus erythematosus or lupus nephritis, comprising a composition containing PIBF1 as an active ingredient and an instruction manual.

9. A method for characterizing responders to a therapeutic agent for the treatment of systemic lupus erythematosus or lupus nephritis comprising the following steps: (S1) a step of measuring the level of CXCL10 in a blood sample separated from a subject; and (S2) If the level of CXCL10 measured in the above step (S1) is increased compared to the control group, a step of determining the patient as a responder to a treatment for systemic lupus erythematosus or lupus nephritis; A method wherein the above treatment comprises PIBF1 as an active ingredient.

10. A composition for determining a patient with systemic lupus erythematosus or lupus nephritis requiring administration of the composition of claim 1, comprising as an active ingredient a preparation for measuring the level of CXCL10 in blood separated from a subject.

11. Use of PIBF1 or a composition containing it as an active ingredient for preventing, improving or treating systemic lupus erythematosus or lupus nephritis.

12. Use for manufacturing a preparation for preventing, improving or treating systemic lupus erythematosus or lupus nephritis using PIBF1 or a composition containing it as an active ingredient.

13. A method for preventing or treating systemic lupus erythematosus or lupus nephritis, comprising administering PIBF1 or a composition containing it as an active ingredient to a subject in need thereof.

14. Use of PIBF1 or a composition comprising it as an active ingredient for the treatment of systemic lupus erythematosus or lupus nephritis for characterizing responders.

15. Use of a preparation for measuring the level of CXCL10 in blood isolated from a subject or a composition containing the preparation as an active ingredient for the diagnosis of patients with systemic lupus erythematosus or lupus nephritis.

16. A method for determining a patient with systemic lupus erythematosus or lupus nephritis, comprising a step of measuring the level of CXCL10 in blood separated from a subject using a preparation for measuring the level of CXCL10 in blood separated from a subject or a composition containing the preparation as an active ingredient.

Citation Information

Patent Citations

  • A biomarker composition for diagnosis of lupus nephritis comprising Immunoglobulin binding protein 1

    KR1020180033821A

  • Systemic lupus erythematosus diagnostic assay

    US20100113293A1

  • Methods and compositions for diagnosing or monitoring autoimmune and chronic inflammatory diseases

    US20110262914A1

  • Biomarkers predictive of lupus progression and uses thereof

    US20170269075A1